SMARCB1 Antibody

What is SMARCB1 and what cellular functions does it perform?

SMARCB1 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily b, member 1) functions as a core component of the BAF (hSWI/SNF) chromatin remodeling complex. This ATP-dependent complex plays critical roles in modifying chromatin structure to regulate gene expression. SMARCB1 specifically contributes to the creation of altered chromatin forms that constrain fewer negative supercoils than normal, converting nucleosomes on polynucleosomal arrays into asymmetric structures called altosomes. At the functional level, SMARCB1 stimulates the remodeling activity of SMARCA4/BRG1/BAF190A and participates in promoter activation, such as for the CSF1 gene. SMARCB1 is also crucial for cell cycle control, causing arrest in G0/G1 phase, and plays essential roles in neural development through its inclusion in neural progenitor-specific chromatin remodeling complexes (npBAF) and neuron-specific chromatin remodeling complexes (nBAF) .

What is the molecular structure and cellular localization of SMARCB1?

SMARCB1 is a nuclear protein with a canonical length of 385 amino acid residues and a molecular weight of approximately 44.1 kDa (calculated), though it typically appears at 40-45 kDa in experimental observations. The protein belongs to the SNF5 family and has multiple synonyms including BAF47, INI1, and SNF5L1. SMARCB1 has up to two reported isoforms and is widely expressed across diverse tissue types. Its primary subcellular localization is in the nucleus, consistent with its function in chromatin remodeling and transcriptional regulation. The gene is conserved across multiple species, with orthologs reported in mouse, rat, bovine, frog, chimpanzee, and chicken .

What disease associations does SMARCB1 have that make it relevant for research?

SMARCB1 has significant disease associations, most notably with rhabdoid tumor predisposition syndrome. As a tumor suppressor gene, loss of SMARCB1 function is implicated in the development of malignant rhabdoid tumors and other cancers. The gene has also been associated with MRD15 (Mental Retardation, Autosomal Dominant 15). The critical role of SMARCB1 in the BAF complex makes it relevant for studying chromatin regulation in various pathological conditions. Its involvement in neural development through npBAF and nBAF complexes further highlights its importance in neurodevelopmental research. The transition from proliferating neural stem/progenitor cells to postmitotic neurons requires a switch in the composition of these complexes, with SMARCB1 playing a key role in this developmental process .

What are the optimal applications for SMARCB1 antibody detection?

SMARCB1 antibodies have been validated across multiple detection techniques with varying optimal dilutions:

For all applications, it is recommended to empirically optimize antibody concentration for specific experimental conditions and sample types. Over 110 scientific publications have reported using SMARCB1 antibodies in research, with Western Blot being the most common application .

How should I validate SMARCB1 antibody specificity for my experiments?

Comprehensive validation of SMARCB1 antibody specificity should employ multiple approaches:

• Knockout/knockdown controls: Use SMARCB1 knockout cell lines (e.g., SMARCB1 knockout HEK-293T cells) to confirm antibody specificity. The absence of signal in knockout samples provides strong evidence for specificity.

• Multiple cell lines: Test the antibody across diverse cell types known to express SMARCB1 (e.g., HEK293T, HeLa, K-562, Daudi cells) to confirm consistent detection at the expected molecular weight.

• Loading controls: Always include appropriate loading controls (e.g., GAPDH) to normalize protein loading and ensure reliable quantification.

• Competition assays: When possible, perform peptide competition assays using the immunizing peptide to confirm binding specificity.

• Multiple antibody validation: Use antibodies from different vendors or those recognizing different epitopes to corroborate findings.

As demonstrated in validation data, specific SMARCB1 antibodies show clear bands at the expected molecular weight (40-50 kDa) in wild-type cells but no signal in knockout lines, confirming their specificity .

What tissue-specific considerations should be made when using SMARCB1 antibodies for IHC?

When performing immunohistochemistry with SMARCB1 antibodies, several tissue-specific considerations are crucial:

• Antigen retrieval optimization: SMARCB1 detection in tissue sections typically requires heat-mediated antigen retrieval. For optimal results, use Tris/EDTA buffer at pH 9.0, though citrate buffer at pH 6.0 can serve as an alternative for some tissue types.

• Tissue-specific positive controls: Include known positive controls such as human lymphoma tissue or human prostate cancer tissue, where SMARCB1 expression has been well-documented.

• Nuclear staining pattern: Ensure proper nuclear localization of staining, as cytoplasmic signal may indicate non-specific binding or technical issues.

• Fixation considerations: Overfixation can mask SMARCB1 epitopes; standardize fixation protocols across experimental samples.

• Dilution optimization: Start with the recommended dilution range (1:20-1:200) but optimize specifically for each tissue type, as cellular context can affect epitope accessibility.

• Loss of expression interpretation: In certain tumors, particularly rhabdoid tumors, loss of SMARCB1 expression is diagnostically significant. Ensure proper controls to distinguish true loss from technical failure .

How should I design experiments to study SMARCB1 interactions with other BAF complex components?

To effectively study SMARCB1 interactions with other BAF complex components, a multi-method approach is recommended:

• Co-immunoprecipitation (Co-IP): Using validated SMARCB1 antibodies (0.5-4.0 μg for 1.0-3.0 mg of total protein lysate), immunoprecipitate SMARCB1 and probe for associated BAF complex components like SMARCA4/BRG1. Include appropriate negative controls (e.g., non-specific IgG, PBS instead of cell lysate).

• Proximity ligation assay (PLA): This technique allows visualization of protein-protein interactions in situ, providing spatial information about SMARCB1 interactions within the nuclear compartment.

• Chromatin immunoprecipitation (ChIP): To study SMARCB1 at specific genomic loci alongside other BAF components, perform sequential ChIP or re-ChIP experiments.

• CRISPR-Cas9 genetic editing: Generate cell lines with tagged SMARCB1 or with specific mutations to assess how alterations affect complex assembly.

• Mass spectrometry: After immunoprecipitation with SMARCB1 antibodies, perform mass spectrometry to identify novel interacting partners or changes in BAF complex composition under different conditions.

This integrated approach provides complementary data on physical interactions, genomic co-localization, and functional relationships between SMARCB1 and other chromatin remodeling factors .

What controls are essential when studying SMARCB1 loss in tumor models?

When investigating SMARCB1 loss in tumor models, comprehensive controls are essential to ensure reliable interpretation:

• Antibody validation controls:

  • Use multiple SMARCB1 antibodies targeting different epitopes

  • Include known SMARCB1-positive and SMARCB1-negative cell lines/tissues

  • Always run parallel staining for internal control proteins unaffected by SMARCB1 status

• Genetic validation controls:

  • Complement protein detection with mRNA analysis (RT-qPCR or RNA-seq)

  • Where possible, verify SMARCB1 genetic status through sequencing

• Experimental model controls:

  • For induced SMARCB1 knockdown/knockout models, include appropriate vector controls

  • For tumor studies, include adjacent normal tissue and non-related control tissues

  • Use isogenic cell lines differing only in SMARCB1 status

• Rescue experiments:

  • Perform functional rescue by reintroducing wild-type SMARCB1 to demonstrate phenotype reversibility

  • Include mutant SMARCB1 variants as additional controls

• Temporal controls:

  • For inducible systems, establish appropriate time-course analyses to distinguish direct from indirect effects

These comprehensive controls ensure that observed phenotypes can be directly attributed to SMARCB1 loss rather than experimental artifacts or secondary effects .

How can I effectively study SMARCB1 chromatin remodeling activity in different cellular contexts?

To comprehensively assess SMARCB1 chromatin remodeling activity across different cellular contexts, implement these advanced methodological approaches:

• Chromatin accessibility assays: Combine SMARCB1 ChIP-seq with ATAC-seq or DNase-seq to correlate SMARCB1 genomic localization with changes in chromatin accessibility. This reveals direct effects of SMARCB1-containing BAF complexes on chromatin structure.

• Nucleosome positioning analysis: MNase-seq following SMARCB1 manipulation can reveal alterations in nucleosome positioning and occupancy, providing mechanistic insights into how SMARCB1 contributes to chromatin landscape changes.

• Hi-C chromatin conformation: Assess how SMARCB1 loss or mutation affects three-dimensional genome organization through chromosome conformation capture techniques, identifying long-range regulatory interactions dependent on SMARCB1 activity.

• Single-cell approaches: Apply single-cell ATAC-seq or ChIP-seq to understand cell-type-specific functions of SMARCB1, particularly important in heterogeneous tissues or differentiation systems.

• Live-cell imaging: Utilize fluorescently tagged SMARCB1 combined with advanced microscopy to track dynamic chromatin interactions in real-time during cellular processes like differentiation or response to stimuli.

• Conditional expression systems: Implement tissue-specific or temporally regulated SMARCB1 knockout/knockin models to dissect context-dependent functions, particularly important when studying developmental roles.

This multi-faceted approach provides mechanistic insights into how SMARCB1-containing BAF complexes differentially regulate chromatin in distinct cellular environments .

What are the best approaches for studying the role of SMARCB1 in neural development?

Studying SMARCB1's role in neural development requires specialized approaches addressing its unique functions in neural progenitor-specific chromatin remodeling complex (npBAF) and neuron-specific chromatin remodeling complex (nBAF):

• Developmental time-course analysis: Implement temporally regulated SMARCB1 manipulation at defined developmental stages using Cre-loxP systems under neural progenitor-specific promoters (e.g., Nestin-Cre) or neuron-specific promoters (e.g., Syn1-Cre).

• BAF complex compositional analysis: Track the developmental switch from npBAF to nBAF complexes through co-immunoprecipitation with SMARCB1 antibodies followed by mass spectrometry to identify stage-specific interacting partners.

• Cerebral organoid models: Utilize human iPSC-derived brain organoids with SMARCB1 modifications to model neurodevelopmental processes in a three-dimensional context more representative of human brain development.

• Single-cell transcriptomics: Implement scRNA-seq on developing neural tissues with SMARCB1 manipulation to identify cell-type-specific transcriptional programs regulated by SMARCB1-containing complexes.

• Dendritic morphology analysis: As SMARCB1 (in nBAF complexes) regulates genes essential for dendrite growth, conduct detailed morphological analyses of neurons following SMARCB1 manipulation using techniques like Golgi staining or fluorescent reporter systems.

• Electrophysiological assessment: Combine patch-clamp recordings with SMARCB1 manipulation to correlate chromatin remodeling activities with functional neuronal properties and circuit formation.

These methodologies collectively address the complex role of SMARCB1 in neural stem cell maintenance, neuronal differentiation, and neurite development .

How can I differentiate between direct and indirect effects of SMARCB1 loss in transcriptional studies?

Distinguishing direct from indirect transcriptional effects following SMARCB1 loss presents a significant challenge that requires integrated genomic approaches:

• Temporal transcriptome analysis: Implement time-course RNA-seq following acute SMARCB1 depletion (e.g., using inducible degradation systems or rapid siRNA transfection) to identify immediate transcriptional changes (likely direct) versus later responses (potentially indirect).

• Integrated ChIP-seq and RNA-seq: Combine SMARCB1 ChIP-seq with RNA-seq to correlate physical binding with expression changes. Genes both bound by SMARCB1 and immediately altered upon SMARCB1 loss represent strong candidates for direct regulation.

• Nascent RNA analysis: Techniques like PRO-seq or GRO-seq measure newly synthesized RNA, allowing detection of immediate transcriptional responses before secondary effects emerge.

• Targeted validation with CRISPRi: Use CRISPRi to specifically inhibit SMARCB1 binding at individual loci (rather than depleting the protein globally) to confirm direct regulatory relationships.

• Motif analysis and transcription factor co-occupancy: Identify transcription factor motifs enriched at SMARCB1 binding sites and perform ChIP-seq for these factors to distinguish between SMARCB1-dependent and independent regulation.

• Synthetic rescue approaches: Introduce modified SMARCB1 variants that restore specific interactions while disrupting others to dissect which protein-protein interactions mediate particular transcriptional responses.

This integrated strategy helps create a hierarchical model of gene regulation following SMARCB1 loss, distinguishing primary from secondary effects .

What are common causes of false negative SMARCB1 immunostaining results?

False negative SMARCB1 immunostaining can arise from multiple technical factors that must be systematically addressed:

• Inadequate antigen retrieval: SMARCB1 epitopes are particularly sensitive to fixation effects. For optimal results, test both high-pH Tris/EDTA buffer (pH 9.0) and standard citrate buffer (pH 6.0) with sufficient heating time (20+ minutes).

• Antibody selection issues: Not all antibodies perform equally across applications. For IHC specifically, use antibodies explicitly validated for this application rather than those optimized for Western blot.

• Fixation variables: Overfixation in formalin can mask SMARCB1 epitopes. Standardize fixation time (24-48 hours recommended) and consider testing multiple blocks if available.

• Dilution optimization failure: The recommended dilution range (1:20-1:200) is broad. Create a dilution series to identify optimal concentration for specific tissue types and fixation conditions.

• Detection system sensitivity: When nuclear staining is weak, switch to more sensitive detection systems like polymer-based detection or tyramide signal amplification.

• Internal control assessment: Always include internal non-neoplastic cells (lymphocytes, endothelial cells) that should maintain SMARCB1 expression. Their absence suggests technical failure rather than true biological loss.

• Tissue heterogeneity: In some tumor specimens, SMARCB1 loss may be focal. Evaluate multiple areas and consider the possibility of heterogeneous expression .

How can I resolve inconsistent Western blot results when using SMARCB1 antibodies?

Inconsistent Western blot results with SMARCB1 antibodies can be systematically addressed through these methodological improvements:

• Sample preparation optimization:

  • Ensure complete nuclear protein extraction using appropriate lysis buffers containing nuclear isolation components

  • Incorporate protease inhibitors to prevent degradation

  • Standardize protein quantification methods for consistent loading

• Antibody selection and validation:

  • Test multiple antibodies targeting different SMARCB1 epitopes

  • Verify antibody specificity using knockout controls

  • For polyclonal antibodies, consider lot-to-lot variation effects

• Technical parameters adjustment:

  • Optimize blocking conditions (5% milk vs. BSA) to reduce background

  • Test different transfer methods (wet vs. semi-dry) for efficient protein transfer

  • Adjust antibody incubation time and temperature (overnight at 4°C often yields better results than short room-temperature incubations)

• Signal detection troubleshooting:

  • For weak signals, increase antibody concentration (within 1:500-1:2000 range) or extend exposure time

  • For high background, implement additional washing steps or adjust secondary antibody dilution

  • Consider enhanced chemiluminescence systems for improved sensitivity

• Positive control inclusion:

  • Always run known positive controls (K-562 or HepG2 cells) alongside experimental samples

  • Create standard curves with positive control dilutions to ensure quantification within linear range

Molecular weight considerations: SMARCB1 should appear at 40-45 kDa; bands at significantly different sizes may represent non-specific binding or post-translational modifications .

How should I interpret contradictory results between different SMARCB1 detection methods?

When faced with contradictory results between different SMARCB1 detection methods, a systematic analytical approach is necessary:

• Method-specific technical limitations assessment:

  • Western blot may fail to detect low-level expression that immunohistochemistry can visualize due to signal amplification

  • Flow cytometry provides quantitative single-cell resolution but may suffer from fixation/permeabilization artifacts

  • RNA-based methods detect transcript but not protein, overlooking post-transcriptional regulation

• Antibody epitope considerations:

  • Different antibodies recognize distinct epitopes that may be differentially affected by:

    • Protein conformation changes in different assays

    • Masking by protein-protein interactions

    • Post-translational modifications

    • Fixation-induced epitope alteration

• Validation hierarchy implementation:

  • Establish a validation hierarchy with knockout/knockdown controls as gold standard

  • Complement protein detection with mRNA analysis (RT-qPCR)

  • Consider orthogonal approaches (mass spectrometry) for definitive protein identification

• Biological interpretation framework:

  • Consider subcellular localization differences (nuclear vs. cytoplasmic signals)

  • Evaluate possibility of isoform-specific detection

  • Assess heterogeneity within sample populations

• Reconciliation strategies:

  • For critical findings, implement multiple detection methods with different antibodies

  • Report discrepancies transparently in publications

  • When possible, favor functional assays to complement detection methods

How can I effectively use SMARCB1 antibodies in single-cell proteomic applications?

Integrating SMARCB1 antibodies into single-cell proteomic workflows requires specialized approaches to overcome technical challenges:

• Mass cytometry (CyTOF) implementation:

  • Conjugate anti-SMARCB1 antibodies with rare earth metals

  • Optimize permeabilization protocols for nuclear antigen access

  • Include careful antibody titration to determine optimal signal-to-noise ratio

  • Create multiplexed panels incorporating key BAF complex components and lineage markers

• Microfluidic-based single-cell Western blotting:

  • Adapt SMARCB1 antibody concentrations (typically higher than conventional Western blot)

  • Implement on-chip fixation and permeabilization optimization

  • Include simultaneous detection of multiple proteins to contextualize SMARCB1 expression

• CITE-seq adaptation for nuclear factors:

  • Develop nuclear-targeted oligo-conjugated SMARCB1 antibodies

  • Optimize nuclear permeabilization while preserving RNA integrity

  • Implement computational approaches to correlate protein levels with transcriptional states

• Imaging mass cytometry:

  • Use metal-conjugated SMARCB1 antibodies for spatial proteomics

  • Implement tissue preparation protocols preserving both antigenicity and spatial organization

  • Develop image analysis pipelines to quantify nuclear SMARCB1 in tissue context

• Proximity extension assays:

  • Adapt proximity ligation or extension assays for SMARCB1 detection at single-cell level

  • Combine with microfluidic platforms for high-throughput analysis

These emerging technologies allow researchers to examine SMARCB1 expression heterogeneity within complex tissues and correlate its levels with cell state transitions or pathological processes .

What approaches should I use to study post-translational modifications of SMARCB1?

Investigating post-translational modifications (PTMs) of SMARCB1 requires specialized methodologies beyond standard antibody applications:

• Phospho-specific antibody approaches:

  • Utilize phospho-specific SMARCB1 antibodies when available

  • Validate specificity using phosphatase treatment controls

  • Implement phospho-enrichment strategies before Western blotting

• Mass spectrometry-based PTM mapping:

  • Immunoprecipitate SMARCB1 using validated antibodies (0.5-4.0 μg for IP)

  • Perform tryptic digestion and LC-MS/MS analysis

  • Implement neutral loss scanning for phosphorylation detection

  • Use electron-transfer dissociation for complex modification patterns

• PTM-specific functional analysis:

  • Generate phosphomimetic and phospho-deficient SMARCB1 mutants

  • Perform structure-function studies in SMARCB1-deficient backgrounds

  • Analyze cell-cycle dependent modification patterns

• Kinase/enzyme identification strategies:

  • Conduct kinase inhibitor screens combined with PTM detection

  • Perform in vitro kinase assays with purified components

  • Implement proximity labeling to identify modifying enzymes in situ

• Modification crosstalk assessment:

  • Investigate relationships between different modifications (phosphorylation, acetylation, ubiquitination)

  • Perform sequential immunoprecipitation to isolate specific modified subpopulations

• Computational PTM site prediction:

  • Utilize bioinformatic tools to predict potential modification sites

  • Integrate with protein structure data to assess functional significance

These approaches provide critical insights into how SMARCB1 activity is regulated post-translationally, potentially revealing new therapeutic opportunities in SMARCB1-related disorders .

How can I design experiments to investigate the role of SMARCB1 in enhancer-promoter interactions?

Investigating SMARCB1's role in enhancer-promoter interactions requires integrative genomic approaches that capture both physical interactions and functional outcomes:

• Hi-C and derivative techniques:

  • Perform Hi-C or Micro-C in wild-type versus SMARCB1-depleted cells

  • Implement more targeted approaches like Capture-C or HiChIP focused on specific enhancer-promoter pairs

  • Analyze changes in topologically associating domains (TADs) and chromatin loops

• Functional enhancer testing:

  • Utilize CRISPR interference to selectively inhibit SMARCB1 binding at specific enhancers

  • Implement STARR-seq or massively parallel reporter assays to assess enhancer activity dependencies

  • Design specific enhancer-promoter reporters to test SMARCB1 requirements

• Multi-omics integration:

  • Combine SMARCB1 ChIP-seq with ATAC-seq to identify SMARCB1-dependent accessible regions

  • Overlay with H3K27ac and H3K4me1 ChIP-seq to define active enhancers

  • Integrate RNA-seq to correlate structural changes with expression outcomes

• Live-cell imaging approaches:

  • Implement genomic visualization systems (e.g., CRISPR-dCas9 with fluorescent tags)

  • Directly visualize enhancer-promoter proximity in living cells under normal and SMARCB1-depleted conditions

  • Perform real-time measurements during cellular transitions

• Transcription factor co-occupancy analysis:

  • Identify transcription factors co-localizing with SMARCB1 at enhancers

  • Perform sequential ChIP to confirm simultaneous binding

  • Test dependency relationships through depletion studies

These complementary approaches collectively reveal how SMARCB1-containing BAF complexes facilitate or stabilize enhancer-promoter interactions to regulate gene expression programs .

What emerging technologies will enhance SMARCB1 antibody applications in research?

Several emerging technologies are poised to revolutionize SMARCB1 research applications in the near future:

• Spatially resolved transcriptomics integration: Combined protein-RNA detection methods like Visium with immunohistochemistry will enable correlation between SMARCB1 protein levels and localized transcriptional programs within intact tissue architecture.

• CUT&Tag and CUT&RUN advancements: These techniques require significantly fewer cells than traditional ChIP-seq, enabling SMARCB1 binding site identification from limited clinical samples or rare cell populations.

• Machine learning-based image analysis: Advanced computational approaches will enhance quantification of SMARCB1 immunohistochemistry, enabling more precise correlation with clinical outcomes and improved diagnostic accuracy.

• Liquid biopsy applications: Development of highly sensitive detection methods may enable monitoring of SMARCB1 protein complexes or fragments in circulation, potentially offering non-invasive diagnostic approaches for SMARCB1-deficient tumors.

• Live-cell protein tracking: New generations of split fluorescent proteins and self-labeling tags will enable real-time tracking of SMARCB1 dynamics during cellular processes without compromising function.

• Targeted protein degradation approaches: Protein degradation technologies targeting SMARCB1 or specific interactions will provide more precise tools for studying complex-specific functions than traditional knockdown approaches.

These technological advances will expand our understanding of SMARCB1's multifaceted roles in chromatin regulation and disease pathogenesis, potentially opening new therapeutic avenues for SMARCB1-related disorders .

What are the most important considerations when reporting SMARCB1 antibody results in publications?

When publishing research involving SMARCB1 antibodies, several critical reporting standards should be observed:

• Complete antibody documentation:

  • Provide full antibody details: manufacturer, catalog number, lot number, RRID identifier

  • Specify host species, clonality (monoclonal/polyclonal), and target epitope when available

  • Document the exact dilutions used for each application

• Validation evidence inclusion:

  • Include specific validation data or reference validation studies

  • Document specificity controls (knockout/knockdown)

  • When using multiple antibodies, clearly report concordance or discrepancies

• Methodological transparency:

  • Detail all experimental parameters (fixation methods, antigen retrieval conditions, detection systems)

  • Specify image acquisition settings and any post-acquisition processing

  • Provide complete protocols or references to detailed methods

• Quantification methodology:

  • Explain scoring systems for immunohistochemistry

  • Detail normalization methods for Western blot quantification

  • Report statistical approaches and sample sizes

• Reproducibility considerations:

  • Report the number of experimental replicates

  • Document consistency across technical and biological replicates

  • Acknowledge any failed experiments or inconsistent results

• Data availability:

  • Provide access to original unprocessed images when possible

  • Consider depositing raw data in appropriate repositories

These comprehensive reporting standards ensure experimental reproducibility and enable proper evaluation of SMARCB1-related findings in the scientific literature .

How will understanding of SMARCB1's role in chromatin regulation impact future therapeutic approaches?

Emerging insights into SMARCB1's role in chromatin regulation are revealing promising therapeutic avenues:

• Synthetic lethality approaches: The loss of SMARCB1 in certain cancers creates specific vulnerabilities that can be therapeutically targeted. Research has identified dependencies on residual SWI/SNF components, specific transcriptional programs, or metabolic adaptations that emerge following SMARCB1 loss.

• Epigenetic modifier targeting: SMARCB1 loss often leads to aberrant activity of other chromatin regulators (e.g., EZH2). Inhibitors of these compensatory pathways show promise in SMARCB1-deficient cancers, suggesting a paradigm of targeting epigenetic imbalances.

• Transcriptional addiction exploitation: SMARCB1-deficient cells frequently develop dependencies on specific transcription factors. Small molecule approaches targeting transcriptional CDKs (e.g., CDK7, CDK9) or transcription factor complexes may selectively affect SMARCB1-mutant cells.

• BAF complex modulation: Emerging technologies enabling selective degradation or inhibition of specific protein-protein interactions may allow precise modulation of residual BAF complex activity in SMARCB1-deficient contexts.

• Developmental pathway targeting: Given SMARCB1's role in neural development, neurodevelopmental disorders associated with SMARCB1 dysregulation may benefit from therapies targeting specific developmental signaling pathways disrupted by SMARCB1 abnormalities.

• Immunotherapeutic opportunities: The genomic instability and altered antigen presentation associated with SMARCB1 loss may create unique immunotherapeutic opportunities, particularly in combination with epigenetic modifiers.